(ED NOTE:  As usual, I blamethe Proofreaders for errors in taste in the pictures chosen to accompany the stories.   Of course, the importance of this article is that big Healthcare Companies, in this instance, are sharing information; now we need Pharma Research companies, and other research labs to do the same, so as to no repeat the same tests, etc, but maybe that is impossible to ask)


February 20, 2014

NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed an agreement with preferred provider organization Prime Health Services to offer its ConfirmMDx for Prostate Cancer test to Prime Health’s members.

MDxHealth said the agreement covers all 50 states and extends ConfirmMDx’s testing to around 144 million covered lives throughout the US. Prime Health serves more than 700,000 providers and facilities nationwide through its Prime Health Delivery System.

ConfirmMDx is an epigenetics-based test launched in May 2012 that uses tissue obtained from a previous negative prostate biopsy to differentiate patients with true negative results from those who are at high risk for missed cancer. During the past several months, MDxHealth has signed on several managed care firms, includingHealthSmart, Fortified Provider Network, FedMed, and America’s Choice Provider Network to provide access to the test.

“Both the payor and urology community are adopting ConfirmMDx to improve patient risk stratification with a non-invasive, cost-effective means to help reduce unnecessary repeat prostate biopsies and the associated healthcare costs, and to improve outcomes by aiding in the earlier detection of men with potentially lethal disease,” Jan Groen, CEO of MDxHealth, said in a statement. “As we capture more contracts, like this new agreement with Prime Health, and our experience with existing payors increases, we expect to shorten the reimbursement cycle as we transition more payors to an accrual basis and increase revenue recognition in 2014.”


No comments

Be the first one to leave a comment.

Post a Comment